IMPORTANT STEMLINE THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York against Stemline Therapeutics, Inc.

NEW YORK, Feb. 07, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP   announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ:STML) on behalf of investors that acquired Stemline securities: (1) pursuant and/or traceable to Stemline’s secondary public offering on January 20, 2017; and/or (2) on the open market during the period from January 19, 2017 through February 1, 2017 (the “Class Period”).

Investors  who have incurred losses in shares of Stemline Therapeutics, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you   have   purchased shares of Stemline Therapeutics, Inc. within the class period and would like to assist with the litigation process, you may, no later than April 4, 2017, request that the Court appoint you lead plaintiff of the proposed class.

Stemline is a clinical stage biopharmaceutical company that focuses on proprietary oncology therapeutics.

On February 2, 2017, TheStreet.com reported that on January 18, 2017, one day prior to Stemline’s Secondary Public Offering (SPO), a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect. Also on February 2, 2017, Stemline issued a press release entitled “Stemline Therapeutics Provides Update on Pivotal BPDCN Trial,” confirming the death reported by TheStreet.com.

This material and previously undisclosed news caused the shares of Stemline to fall from $9.75 to $5.60 per share on February 2, 2017, decline of 43% for the day.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please  immediately  contact  Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.